{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1383670320120855555.json","@type":"Researcher","foaf:Person":[{"foaf:name":[{"@value":"Yoshio Hayashi"}],"foaf:familyName":[{"@value":"Hayashi"}],"foaf:givenName":[{"@value":"Yoshio"}]}],"career":[{"institution":{"notation":[{"@value":"Department of Medicinal Chemistry, Tokyo University of Pharmacy and Life Sciences, Tokyo 192-0392, Japan"}]}}],"product":[{"@id":"https://cir.nii.ac.jp/crid/1363670320120855552","@type":"Article","productIdentifier":[{"@type":"DOI","@value":"10.1021/acs.jmedchem.5b01461"},{"@type":"URI","@value":"http://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.5b01461"},{"@type":"URI","@value":"https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.5b01461"},{"@type":"PMID","@value":"26878082"}],"notation":[{"@value":"An Overview of Severe Acute Respiratory Syndrome–Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy"}],"relation":[{"type":"creator"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1021/acs.jmedchem.5b01461_6rdYaXIMd1KAslsOxPBdncyIcdn"},{"@type":"OPENAIRE","@value":"doi_dedup___::e22c9fa383b3956265fc3f5de99d19f6_6rdYaXIMd1KAslsOxPBdncyIcdn"}]}